Discounted Biotech Sellers, Rich Pharma Buyers May Finally Revive M&A Activity in Healthcare
![](https://www.mcalindenresearchpartners.com/wp-content/uploads/2022/05/cdc-IFpQtennlj8-unsplash-1024x683.jpg)
The acquisition of biotechnology firms is one of the most common ways big pharma replenishes their pipeline of new drugs. However,…
McAlinden Research PartnersMay 12, 2022